14
Dec
2023
Pfizer Closes Seagen, a Historic CRISPR Approval, & FTC Takes Shot at Sanofi
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Dec
2023
The Small Molecule Drug Discovery Renaissance: Jeff Jonker on The Long Run
Today’s guest is on The Long Run is Jeff Jonker. He’s the CEO of San Diego-based Belharra Therapeutics. It’s a startup that came out of stealth mode in January 2023 with a $50 million Series A financing from Versant Ventures, and a partnership with Genentech. I wrote about it at the time on TimmermanReport.com and am providing a link for... Read More
7
Dec
2023
AbbVie Buys Cerevel, Roche Buys Carmot, & Crowley Steps Into the Lion’s Den
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Dec
2023
Third Rock Joins F-Prime, Omega in $90M Round for ARTBIO’s Targeted Radiotherapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Dec
2023
Join Me and a Terrific Lineup for ‘Bridging the Gap’ Jan. 23 in Cambridge, Mass.
I’m excited to announce “Bridging the Gap.” It’s an event for the biotech innovation community Jan. 23 in Cambridge, Mass. An outstanding group of speakers is coming together to support a new generation of scientists through the Damon Runyon Cancer Research Foundation. Time: Noon-7 pm Date: Jan. 23 Place: The Engine. 750 Main St., Cambridge, Mass. Tickets are limited. Buy... Read More
30
Nov
2023
ImmunoGen’s Payday, FDA Jolts CAR-T Field, & Another Dupixent Win
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Nov
2023
The Final Frontier of Brain Science: Nancy Stagliano on The Long Run
Today’s guest on The Long Run is Nancy Stagliano. She’s the CEO of South San Francisco-based Neuron23. The company is privately held and was started in late 2018. The idea, like we’ve seen in oncology, is to develop targeted therapies for molecularly-defined subgroups of patients with Parkinson’s, Alzheimer’s, and other common neurodegenerative diseases. Nancy is a neuroscientist by training. She... Read More
16
Nov
2023
UK Clears 1st CRISPR Drug, Lilly’s siRNA for CV Disease & Blackstone’s Anti-Clotting Win
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Nov
2023
Leading the Fight Against Infectious Disease: Diana Brainard on The Long Run
Today’s guest is Diana Brainard. She’s the CEO of Waltham, Mass.-based AlloVir. AlloVir is developing off-the-shelf T cell therapies to fight common viruses. The company is developing these T cells, from donors, and modifying them so they can be given to patients with weakened immune systems. The company’s lead T-cell therapy candidate is made to fight six common viruses, including... Read More
9
Nov
2023
Obesity Drug Rivalry Intensifies, Takeda’s Big FDA Week, & Vor Takes on AML
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Nov
2023
Vor Bio Shows CRISPR’d Stem Cell Transplants Take Hold in AML Patients, Enable ADCs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Nov
2023
Kynexis Gets €57M to Pursue New Treatment Pathway for Schizophrenia
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Nov
2023
ProfoundBio, Challenging ImmunoGen, Delivers Responses in First Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Nov
2023
Lilly Doubles Down on Base Editing, BioMarin CEO Exits, and Layoffs Mount
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Nov
2023
Investing in the Future of Medicine: Reid Huber on The Long Run
Today’s guest on the The Long Run is Reid Huber. He’s a partner at Third Rock Ventures in Boston. Third Rock is known in biotech as one of the venture firms that creates new companies that seek to turn groundbreaking science into new medicines. Since its founding in 2007, Third Rock has put together a portfolio of 62 companies that... Read More
1
Nov
2023
Gate Bioscience, Backed by Versant, A16Z, Arch, Gets $60M to Block Protein Secretion
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Oct
2023
Nimbus HPK1 Inhibitor Activates Immune System Against Tumors in Early Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Oct
2023
Merck’s ADC Wager, Roche Enters TL1A Rivalry, & OrbiMed Signals Time to Buy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2023
Aiolos Bio, With $245M from Atlas, Bain, Aims at TSLP for Asthma
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Oct
2023
Thermo’s $3.1B Proteomics Bet, UCB’s Rare Two-Fer, & More Cutbacks
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.